The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Novel targeted therapies for CLL
Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, explores novel, targeted therapies for chronic lymphocytic leukemia (CLL), including second-generation BTK inhibitors, CD20 targeting antibodies, CAR T-cell therapy as well as the importance of combination approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
